Problems in the development of target-based drugs

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue SUPPL., 2000, Pages

  Saijo, Nagahiro ^a   Tamura, Tomohide ^a   Nishio, Kazuto ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Clinical endpoint; Farnesyl transferase inhibitor; Target based drug; Time to progression; Tumor shrinkage

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG RESEARCH; DRUG TOLERABILITY; PRIORITY JOURNAL;

EID: 0033758919     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014049     Document Type: Article

References (8)

1. Farnesyltransferase inhibition: Use of surrogate markets
2. Novel anticancer drug discovery
3. Phase I and II trials of novel anticancer agents: Endpoints, efficacy and existentialism
4. Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
5. New phase I trial methodology
6. Development of target-based antineoplastic agents
7. There are no bad anticancer agents, only bad clinical trial designs. Twenty-first Richard and Linda Rosenthal Foundation Award Lecture
8. Novel anti-cancer agents in development: Exciting prospects and new challenges